TW202133886A - 用於增強免疫及腫瘤治療之方法 - Google Patents

用於增強免疫及腫瘤治療之方法 Download PDF

Info

Publication number
TW202133886A
TW202133886A TW109142933A TW109142933A TW202133886A TW 202133886 A TW202133886 A TW 202133886A TW 109142933 A TW109142933 A TW 109142933A TW 109142933 A TW109142933 A TW 109142933A TW 202133886 A TW202133886 A TW 202133886A
Authority
TW
Taiwan
Prior art keywords
tumor
lesion
cells
cancer
tumors
Prior art date
Application number
TW109142933A
Other languages
English (en)
Chinese (zh)
Inventor
古茲曼 馬吉爾 蓋西亞
俊翎 方
艾米 索恩
蜜雪兒 許
Original Assignee
美商樂天醫藥生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商樂天醫藥生技股份有限公司 filed Critical 美商樂天醫藥生技股份有限公司
Publication of TW202133886A publication Critical patent/TW202133886A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109142933A 2019-12-06 2020-12-04 用於增強免疫及腫瘤治療之方法 TW202133886A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962945053P 2019-12-06 2019-12-06
US62/945,053 2019-12-06

Publications (1)

Publication Number Publication Date
TW202133886A true TW202133886A (zh) 2021-09-16

Family

ID=73856374

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109142933A TW202133886A (zh) 2019-12-06 2020-12-04 用於增強免疫及腫瘤治療之方法

Country Status (6)

Country Link
US (1) US20230028062A1 (https=)
EP (1) EP4069300A1 (https=)
JP (1) JP2023505222A (https=)
CN (1) CN115052631A (https=)
TW (1) TW202133886A (https=)
WO (1) WO2021113734A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2889904T3 (es) 2015-08-18 2022-01-14 Rakuten Medical Inc Conjugados de colorante de ftalocianina y su almacenamiento
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
AU2023221861A1 (en) * 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
CN115364238B (zh) * 2022-08-16 2024-02-02 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US11154620B2 (en) * 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
ES2889904T3 (es) * 2015-08-18 2022-01-14 Rakuten Medical Inc Conjugados de colorante de ftalocianina y su almacenamiento
CA3070469C (en) 2016-10-25 2022-06-21 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
CN115943306A (zh) * 2019-03-29 2023-04-07 乐天医药生技股份有限公司 用于光免疫疗法的方法和相关生物标志物
CN114423453A (zh) * 2019-07-30 2022-04-29 乐天医药生技股份有限公司 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)

Also Published As

Publication number Publication date
CN115052631A (zh) 2022-09-13
US20230028062A1 (en) 2023-01-26
WO2021113734A1 (en) 2021-06-10
EP4069300A1 (en) 2022-10-12
JP2023505222A (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
KR20190120792A (ko) 폐암의 치료를 위한 항-pd-1 항체
JP2021529741A (ja) がん治療
TW202133886A (zh) 用於增強免疫及腫瘤治療之方法
KR102314003B1 (ko) 종양성 질병들에 대한 치료
JP2022515188A (ja) がん治療のための組成物および方法
US20220111008A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合
US20230001006A1 (en) Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
CA3218665A1 (en) Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
JP2025542297A (ja) 肺癌の組み合わせ療法
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
TWI916314B (zh) 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака
TW202612735A (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法